$8.170
+0.443 (+5.42%)終値時点
- High
- 8.270
- Open
- 7.830
- VWAP
- 8.05
- Vol
- 36.44K
- Mkt Cap
- 53.36M
- Low
- 7.700
- Amount
- 293.20K
- EV/EBITDA, TTM
- -13.43
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
AI analysis of Rockwell Medical Inc (RMTI)
buyRockwell Medical Inc (RMTI) is a good buy right now due to its current price of $8.17, which is significantly below the analyst price target of $20, indicating a potential upside of over 145%. Additionally, the RSI is at 69.278, suggesting strong momentum, while the stock has shown a 20-day change of +13.63%, indicating positive short-term performance. However, the main risk is the forward P/E ratio of 59.17, which reflects high expectations for future earnings that may not materialize.
Analyst Ratings (3)
H.C. Wainwright
$20
2026-07-09
H.C. Wainwright
2026-07-09
目標株価
$20
H.C. Wainwright
$2
2026-03-30
H.C. Wainwright
2026-03-30
目標株価
$2
Maxim
$4
2026-03-27
Maxim
2026-03-27
目標株価
$4
H.C. Wainwright
$3
2025-11-13
H.C. Wainwright
2025-11-13
目標株価
$3
HC Wainwright & Co.
$3
2025-03-24
HC Wainwright & Co.
2025-03-24
目標株価
$3
バリュエーション指標
イベントタイムライン
ニュース
2.008-14NASDAQ.COMRockwell Medical (RMTI) Q2 2026 Earnings Call Transcript
5.007-22NewsfilterRockwell Medical Appoints New VP of Quality and Regulatory Compliance
8.507-20seekingalphaRockwell Medical Regains Nasdaq Compliance
8.507-20NewsfilterRockwell Medical Regains Nasdaq Compliance
8.506-29stocktwitsRockwell Medical Announces Reverse Stock Split to Regain Nasdaq Compliance
RMTI FAQ — answered by Alphio AI
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Rockwell Medical Inc (RMTI) is a good buy right now due to its current price of $8.17, which is significantly below the analyst price target of $20, indicating a potential upside of over 145%. Additionally, the RSI is at 69.278, suggesting strong momentum, while the stock has shown a 20-day change of +13.63%, indicating positive short-term performance. However, the main risk is the forward P/E ratio of 59.17, which reflects high expectations for future earnings that may not materialize.
3 analysts cover RMTI: 1 rate it Buy, 1 Hold and 1 Sell. The average price target is 3.75.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。